Research ArticleCancer

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Sci. Signal.  25 Mar 2014:
Vol. 7, Issue 318, pp. ra29
DOI: 10.1126/scisignal.2005125

Log in to view full text

As a service to the community, AAAS/Science has made this article free with registration.

Navigate This Article